Ultomiris (ULTOMIRIS) is the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorders in the European Union (EU) approved as a drug (NMOSD).1 Approval by the European Commission [positive opinion](#) It is a Medicines Board human drug and is based on the
Read More
About The Author
